Featured Research

from universities, journals, and other organizations

Antidepressant Drug Tested In Treatment Of Bladder Disease

Date:
March 9, 2005
Source:
Queen's University
Summary:
Queen’s University has been selected as the only Canadian site to test a new antidepressant drug approved by the FDA (U.S. Food and Drug Administration) for its potential to alleviate pain in two common bladder conditions that have no known cause and no effective therapy.

Dr. Curtis Nickel.
Credit: Photo courtesy of Queen's University

Kingston, ON – Queen’s University has been selected as the only Canadian site to test a new antidepressant drug approved by the FDA (U.S. Food and Drug Administration) for its potential to alleviate pain in two common bladder conditions that have no known cause and no effective therapy.

Funded by the U.S. National Institutes of Health (NIH), the research will be carried out at 10 medical centres in the United States and Canada. Dr. Curtis Nickel, professor of Urology at Queen’s and urologist at Kingston General Hospital, heads the Canadian study.

The researchers are recruiting adults newly diagnosed with either painful bladder syndrome (PBS) or interstitial cystitis (IC), to learn if the oral drug amitriptyline will reduce the pain and frequent urination associated with these conditions. An estimated 10 million people worldwide suffer from PBS and IC.

Although amitriptyline is primarily used for depression, the way it works makes it useful fortreating the pain of fibromyalgia, multiple sclerosis, and other chronic pain syndromes, Dr. Nickel explains. “Prior small studies have suggested the drug may be a wise choice for this syndrome as well, because it blocks nerve signals that trigger pain and may also decrease muscle spasms in the bladder, helping to cut both pain and frequent urination.”

The researchers believe that 25 to 75 milligrams of amitriptyline a day may begin relieving IC pain within a week. In contrast, doses in the range of 150 to 300 milligrams are generally used to treat depression.

The 10 centres where testing will take place make up the Interstitial Cystitis Clinical Research Network, sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the NIH, which coordinates all government health care research in the United States.

In 2003, Dr. Nickel and his Kingston Genito-urinary Research Group were awarded an unprecedented four research grants from the NIH, totaling almost $8 million. These studies are now examining alternative, complementary and novel therapies for prostate and bladder disease, in both laboratory research and clinical trials involving more than 3,000 men and women throughout southern Ontario.


Story Source:

The above story is based on materials provided by Queen's University. Note: Materials may be edited for content and length.


Cite This Page:

Queen's University. "Antidepressant Drug Tested In Treatment Of Bladder Disease." ScienceDaily. ScienceDaily, 9 March 2005. <www.sciencedaily.com/releases/2005/03/050308100756.htm>.
Queen's University. (2005, March 9). Antidepressant Drug Tested In Treatment Of Bladder Disease. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2005/03/050308100756.htm
Queen's University. "Antidepressant Drug Tested In Treatment Of Bladder Disease." ScienceDaily. www.sciencedaily.com/releases/2005/03/050308100756.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins